Medical Developments International
Market Cap
AU$397.7m
Last Updated
2021/05/08 08:27 UTC
Data Sources
Company Financials +
Executive Summary
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with limited growth.
Share Price & News
How has Medical Developments International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MVP's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-0.2%
MVP
-1.2%
AU Pharmaceuticals
0.3%
AU Market
1 Year Return
-28.4%
MVP
5.6%
AU Pharmaceuticals
35.9%
AU Market
Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned 35.9% over the past year.
Shareholder returns
| MVP | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.2% | -1.2% | 0.3% |
| 30 Day | 1.5% | -6.1% | 1.8% |
| 90 Day | -14.0% | -8.3% | 2.8% |
| 1 Year | -28.4%-28.4% | 5.8%5.6% | 39.9%35.9% |
| 3 Year | -20.7%-22.0% | -41.6%-42.1% | 30.1%14.7% |
| 5 Year | -8.2%-11.0% | -31.4%-34.7% | 60.1%29.9% |
Long-Term Price Volatility Vs. Market
How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates3 months ago | Simply Wall St
If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% ReturnsValuation
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
5.47x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$5.58) is trading above our estimate of fair value (A$0.26)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: MVP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MVP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (5.5x) compared to the AU Pharmaceuticals industry average (3.2x).
Future Growth
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
51.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MVP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MVP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MVP's revenue (24.1% per year) is forecast to grow faster than the Australian market (5.6% per year).
High Growth Revenue: MVP's revenue (24.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP is forecast to be unprofitable in 3 years.
Past Performance
How has Medical Developments International performed over the past 5 years?
-33.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP is currently unprofitable.
Growing Profit Margin: MVP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: MVP has a negative Return on Equity (-1.49%), as it is currently unprofitable.
Financial Health
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$45.0M) exceed its short term liabilities (A$11.2M).
Long Term Liabilities: MVP's short term assets (A$45.0M) exceed its long term liabilities (A$25.0M).
Debt to Equity History and Analysis
Debt Level: MVP's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: MVP's debt to equity ratio has reduced from 5% to 0.1% over the past 5 years.
Debt Coverage: MVP's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: MVP is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Dividend
What is Medical Developments International current dividend yield, its reliability and sustainability?
0.32%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Brent MacGregor (56 yo)
0.50
Tenure
Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...
Leadership Team
Experienced Management: MVP's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Experienced Board: MVP's board of directors are considered experienced (6.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MVP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.
Top Shareholders
Company Information
Medical Developments International Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$397.657m
- Shares outstanding: 71.26m
- Website: https://medicaldev.com
Number of Employees
Location
- Medical Developments International Limited
- 4 Caribbean Drive
- Scoresby
- Victoria
- 3179
- Australia
Listings
Biography
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical De...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/08 08:27 |
| End of Day Share Price | 2021/05/07 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.